Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of BeiGene's Ociperlimab?
Ociperlimab is a monoclonal antibody commercialized by BeiGene, with a leading Phase III program in Squamous Non-Small Cell Lung Cancer....
Ociperlimab by BeiGene for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Ociperlimab by BeiGene for Cervical Cancer: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Ociperlimab by BeiGene for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to...
Ociperlimab by BeiGene for Small-Cell Lung Cancer: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...
Ociperlimab by BeiGene for Solid Tumor: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Ociperlimab by BeiGene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
Ociperlimab by BeiGene for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Ociperlimab is under clinical development by BeiGene and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to...